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Objective: To evaluate the association between diagnosis of Parkinson disease (PD) and risk factors or early
symptoms amenable to population-based screening.
Methods: A systematic review and meta-analysis of risk factors for PD.
Results: The strongest associations with later diagnosis of PD were found for having a first-degree or any relative
with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65–3.93 and OR, 4.45; 95% CI, 3.39–5.83) or any
relative with tremor (OR, 2.74; 95% CI, 2.10–3.57), constipation (relative risk [RR], 2.34; 95% CI, 1.55–3.53), or lack of
smoking history (current vs never: RR, 0.44; 95% CI, 0.39–0.50), each at least doubling the risk of PD. Further
positive significant associations were found for history of anxiety or depression, pesticide exposure, head injury, rural
living, beta-blockers, farming occupation, and well-water drinking, and negative significant associations were found
for coffee drinking, hypertension, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alcohol, but
not for diabetes mellitus, cancer, oral contraceptive pill use, surgical menopause, hormone replacement therapy,
statins, acetaminophen/paracetamol, aspirin, tea drinking, history of general anesthesia, or gastric ulcers. In the
systematic review, additional associations included negative associations with raised serum urate, and single studies
or studies with conflicting results.
Interpretation: The strongest risk factors associated with later PD diagnosis are having a family history of PD or
tremor, a history of constipation, and lack of smoking history. Further factors also but less strongly contribute to risk
of PD diagnosis or, as some premotor symptoms, require further standardized studies to demonstrate the
magnitude of risk associated with them.
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Idiopathic Parkinson disease (PD) has a prevalence ofapproximately 1% in individuals aged >65 years.1–3
The cause is unknown, but many individual risk factors
for subsequent PD have been suggested. In addition, sev-
eral early nonmotor features have been identified that
precede the diagnosis of PD, sometimes by several
years.4–8 In the past 10 years, there have been a small
number of meta-analyses addressing risk factors for sub-
sequent PD, including smoking, coffee consumption,
pesticide exposure, and use of nonsteroidal anti-inflam-
matory drugs (NSAIDs).9–21 No review has comprehen-
sively assessed predictive risk factors for later diagnosis of
PD. Here we report the largest and most comprehensive
systematic review and meta-analysis to date, which uses
an extensive search of observational studies to calculate
effect sizes of multiple risk factors for PD.
Methods
Search Strategy
We followed PRISMA 2009 guidelines for systematic review
and meta-analysis and the Cochrane Collaboration definition of
both terms.22,23 We undertook a MEDLINE database search
on PubMed from 1966 until March 2011 for studies that
reported factors that could be used to screen for risk of future
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PD. The MeSH terms used were: Constipation OR Sleep Dis-
orders OR Olfaction Disorders OR Smoking OR Color Vision
OR Coffee OR Erectile Dysfunction OR Depression OR
Anxiety OR Mood Disorders OR Hydroxymethylglutaryl-CoA
Reductase Inhibitors OR Anti-Inflammatory Agents, Non-Ste-
roidal OR Solvents OR Pesticides OR Body Mass Index OR
Family OR Risk OR Risk Factors AND Parkinson Disease. We
restricted our analysis to articles written in English. Reference
lists of suitable retrieved articles were hand searched for any
missed references, as were the reference lists of existing relevant
meta-analyses identified in the original search. The final search
was carried out on March 31, 2011.
Inclusion Criteria
Published studies were included if they fulfilled the following
criteria: (1) assessed at least 1 risk factor or early nonmotor
symptom preceding a subsequent diagnosis of PD; (2) reported
original data on relative risks (RRs) or odds ratios (ORs) from
cohorts representative of the general population or case–control
studies with cases defined as patients diagnosed with PD; and
(3) reported data that could be easily obtained in a primary
care environment, that is, those factors that could be deter-
mined through questionnaires or widely available blood tests.
Exclusion Criteria
We excluded review articles, editorials, commentaries, hypothe-
sis papers, letters that reported no new data, meta-analyses, and
abstracts. We excluded studies that (1) reported on treatment
and management of PD, (2) considered associations with estab-
lished PD (ie, not preceding PD), (3) reported factors not easily
ascertainable in the primary care setting (eg, complicated ques-
tionnaires on food frequencies, life events, physical activity,
environmental, solvent or toxin exposures), (4) studied young
onset PD only, (5) did not use a control group or provide
adequate details of the control group (including prevalence
studies), (6) used blood relatives as the control group, (7) were
twin studies, (8) were genetic studies or laboratory studies not
used widely, (9) reported on the same risk factor in a common
study population (where >1 paper reported on the same popu-
lation, we chose the larger and, where equal, the most recent
report), (10) reported on a disease other than PD, or (11)
reported measures other than OR/RR or an equivalent (such as
proportional mortality rate and standardized hospitalization
rate) or from which an OR could not be calculated. If there
was disagreement between authors (A.J.N., J.P.B., A.S.), the
articles were discussed in further detail until an agreement was
reached.
Data Extraction
Study characteristics, a risk estimate of the main study finding,
and secondary findings were extracted for all eligible studies
using a standardized template. Only factors for which a signifi-
cant association was reported in at least 1 study were included.
We included risk factors according to binary measurements (eg,
yes vs no for having a first-degree relative with PD and ever
versus never for alcohol). Data that reported exposures as quar-
tiles or quintiles where the lowest exposure quartile was equal
to zero were converted to binary terms. We excluded associa-
tions reported with medical conditions, drugs or toxins known
to cause symptomatic Parkinsonism such as antipsychotics or
carbon monoxide poisoning. We did not include studies that
reported associations with dementia occurring before onset of
PD, as these cases would not fulfill current criteria for PD and
might include cases of dementia with Lewy bodies.24 For cases,
we used figures for PD instead of Parkinsonism. In studies that
reported data for both young onset and typical age of onset
PD, we excluded the young onset data where possible. If case–
control studies made comparison with >1 control group, the
control group most representative of the healthy general popu-
lation was used. If studies did not report OR, RR, or an equiv-
alent measure, the raw data were reviewed to determine whether
ORs could be calculated. In studies that reported both crude
ORs and adjusted ORs, the adjusted figures were used. After
application of the above methods, no additional studies
required exclusion for quality reasons, according to Newcastle
Ottawa Scale guidelines.25 Length of time that any given factor
preceded onset of PD was not included in the analysis due to
inconsistent reporting of these data.
Statistical Analysis
Where a factor of interest was reported by 2 or more studies in
a consistent manner, these were combined in a meta-analysis;
first separately for case–control and cohort studies (given that
cohort studies are less subject to bias), and second for all studies
together (considering odds ratios from case–control studies to
be estimates of relative risks) to generate a pooled effect size
and 95% confidence interval (CI) for each factor. Heterogeneity
between studies was assessed using the I2 statistic and, where
statistically significant heterogeneity was found (p < 0.05), the
random effects model was used to combine results.26,27 Publica-
tion bias was assessed using the Egger test, and where statisti-
cally significant bias was found, the trim and fill method was
used to adjust for it.28,29 Where data were not given in a way
that could be used in the meta-analysis or where only 1 signifi-
cant study was identified for a given risk factor, the findings of
these studies are only listed in this review. All analyses were per-
formed using Stata version 10 (StataCorp, College Station,
TX).
Results
The literature search yielded 3,856 English language
articles, of which 202 were eligible for inclusion in the
systematic review and 173 of these in the meta-analysis
(Fig 1). The reasons for exclusion of other studies are
given. Full details of studies included in the meta-analysis
are provided (Supplementary Tables 1 and 2). Twenty-
nine articles that could not be included in the meta-anal-
ysis, primarily due to inconsistencies in method of mea-
surement of the studied risk factor or because only 1
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study had reported a significant result on a given factor,
are described and shown (Supplementary Table 3).
Summary results for positive and negative associa-
tions with PD found in the meta-analysis and those
where no association was found are shown in Figures 2
to 4. Significant positive associations were found for fam-
ily history of PD (including any relative and first-degree
relatives only), family history of tremor, preceding consti-
pation, prior mood disorder, exposure to pesticides (or
herbicides or insecticides), previous head injury, rural liv-
ing, beta-blocker use, farming/agricultural occupation,
and well water drinking. Significant negative associations
were found for smoking, coffee drinking, prior hyperten-
sion, use of NSAIDs, calcium channel blocker use, and
alcohol consumption. No significant association was
found for tea drinking; oral contraceptive pill use, pre-
ceding oophorectomy, or hormone replacement therapy;
preceding diabetes mellitus, cancer, or gastric ulcer; use
of statins, acetaminophen/paracetamol, or aspirin; and
prior general anesthetic. In the systematic review, addi-
tional associations that were reported but could not be
categorized consistently included negative associations
with previously raised serum urate and conflicting results
with serum cholesterol (total and various subtypes of se-
rum lipid), obesity, physical activity, any antihypertensive
medication (without further subclassification), education,
and various occupations. Single studies also reported neg-
ative associations with both parents having smoked and
use of smokeless tobacco and positive associations with
family history of any neurologic disease, hyposmia, erec-
tile dysfunction, and excessive daytime sleepiness; com-
plaints of stiffness, imbalance, or tremor; having a first-
degree relative with melanoma; having brown, blond,
and red hair versus black hair; a variety of infectious dis-
eases; immediate-type hypersensitivity; anemia; duration
of fertile life and cumulative length of pregnancies; hav-
ing 3 children; having no children, and various occupa-
tions (see Supplementary Table 3).
Assessment of Publication Bias
According to the Egger test, there was evidence of publi-
cation bias for the factors ever smoking (p ¼ 0.017), cof-
fee drinking (p ¼ 0.002), pesticides (p < 0.001), hor-
mone replacement therapy (p ¼ 0.016), statins (p ¼
0.038), any family history of PD (p ¼ 0.011), family
history of tremor (p ¼ 0.009), and well water drinking
(p ¼ 0.005). Using the trim and fill method to account
for the bias had no effect on the summary estimate for
FIGURE 1: Flowchart of studies included and excluded. OR 5 odds ratio; PD 5 Parkinson disease; RR 5 relative risk.
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FIGURE 2: Factors included for meta-analysis that show a significant positive association with a later diagnosis of Parkinson
disease (PD). CI 5 confidence interval; RR 5 relative risk; OR 5 odds ratio.
FIGURE 3: Factors included for meta-analysis that show a significant negative association with a later diagnosis of Parkinson
disease (PD). CCB’s 5 calcium channel blockers; CI 5 confidence interval; NSAID’s 5 nonsteroidal anti-inflammatory drugs; PD
5 Parkinson disease; RR 5 relative risk; OR 5 odds ratio.
ANNALS of Neurology
896 Volume 72, No. 6
ever smoking, coffee, hormone replacement therapy or
statins, but did diminish the summary estimates for pes-
ticides (RR from 1.78 to 1.53; 95% CI, 1.29–1.80), any
family history of PD (OR from 4.45 to 3.25; 95% CI,
2.43–4.35), family history of tremor (OR from 2.74 to
2.51; 95% CI, 1.96–3.22), and well water drinking (OR
from 1.21 to 1.20; 95% CI, 1.04–1.39); however, the
conclusion that these are statistically significant risk fac-
tors for PD was not altered.
Discussion
This systematic review identified >40 individual risk fac-
tors of potential value for clinical screening. Identified
factors include genetic and environmental risk factors,
associated comorbidities, and medication exposures, as
well as early nonmotor features that may represent the
earliest stages of PD. Although some of these have possi-
ble pathogenic importance and others may represent
early PD, they serve as markers that may help identify
patients who are at high risk of a future diagnosis of PD.
They also provide important information for the earlier
diagnosis of PD, which is often delayed by several
years.30 Of the 30 factors that had data amenable to
meta-analysis, 19 significantly altered risk of future PD
and 11 did not reach significance. This information may
be used to provide the basis for primary care or popula-
tion-based screening as well as improve our understand-
ing of contribution of risk to subsequent PD for each of
these factors.
Family History
Having a family member with PD was the strongest risk
factor for later diagnosis of PD. Although a number of
monogenic causes of PD have been identified, these
account for only about 5% of PD. The excess risk in
those with a family history of PD may be conveyed by
multiple susceptibility loci.31 Familial aggregation may
also be explained by the effect of a shared environment,
for example, concordance for not smoking and avoidance
of coffee, which may influence the risk of PD, either in-
dependently or in conjunction with genetic susceptibility.
Lifestyle and Environmental Factors
A history of smoking reduces the risk of PD by about
36%, with coffee and alcohol (but not tea) consumption
also reducing risk. For smoking, the effect is strongest in
current smokers and weakest in past smokers (56% for
current smokers and 22% for past smokers), but the
association remains significant in all. The nature of this
association is still poorly understood, and cannot be
explained simply by selection bias and confounding.32–36
FIGURE 4: Factors included for meta-analysis that did not show a significant association with a later diagnosis of Parkinson dis-
ease. CI 5 confidence interval; HRT 5 hormone replacement therapy; RR 5 relative risk; OR 5 odds ratio.
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The risk reduction from ever versus never coffee use and
ever versus never alcohol use is approximately 33% and
10%, respectively. A confounding effect of smoking, cof-
fee, and alcohol use in combination has been noted, but
other investigators suggest independence of these
factors.37,38
Pesticide and environmental toxin exposure have
been often implicated in PD causation.13,18,19,39 Despite
differences in populations studied and study design, we
found an overall positive association with ever exposure
to pesticides. Some suggest there may be a greater risk
associated with length of exposure to pesticides, but we
did not evaluate this in our analysis.18,19 The finding
that farming is also associated with subsequent PD may
be in part due to increased likelihood of exposure to
pesticides and other chemicals. Inconsistencies in adjust-
ment between studies made it impossible to determine
the importance of this interaction. Rural living and well
water exposure were also significant positive associations.
We did not include additional surrogates for pesticide
or chemical exposures such as gardening, plantation
work, and solvent exposures requiring more detailed ex-
posure and lifestyle questionnaires. Other occupations
that have been reported to change the risk of PD (but
could not be classified consistently) included being a
physician, clerk, carpenter, or cleaner or having a legal
occupation (increase); production worker, driver, techni-
cian, transport/communication worker, mechanical/fac-
tory or metal worker, sales or service personnel, or engi-
neer (reduced); or construction/extraction worker
(conflicting results).
Head injury may carry increased risk of PD, partic-
ularly in those with repeated head injury and pugilist’s
encephalopathy.40 In our meta-analysis, head injury with
or without loss of consciousness had a significant but
modest effect on the risk of subsequent diagnosis of PD.
Early Symptoms
This systematic review reaffirms the proposed early non-
motor symptoms, which may predate the diagnosis of
PD by several years. Constipation and mood disorders
appear to approximately double an individual’s risk of
subsequent PD in the meta-analysis. Both constipation
and mood disorders have been suggested to correlate
with brainstem involvement that, together with olfactory
bulb involvement, occurs early in PD and later spreads
to the substantia nigra and to the cortex.41 This theory
would also support a role for hyposmia, erectile dysfunc-
tion, and excessive daytime somnolence as early features
of PD, all of which have been reported in single prospec-
tive cohort studies to be associated with significantly
increased risk.42–44 These were large, well-conducted
studies, and there is additional support for smell loss pre-
ceding PD in studies of first-degree relatives of persons with
PD and idiopathic anosmia (see Hawkes5). However, these
clinical syndromes are not routinely tested and are infre-
quently recorded; therefore, no case–control or further
cohort studies fulfilling our criteria that allow meta-analysis
are available at the present time. Rapid eye movement sleep
behavior disorder (RBD) is also believed to precede PD by
a number of years.45,46 Currently, no observational studies
that give ORs or RRs for this association have been
reported. Further studies are required to replicate (for hypo-
smia, erectile dysfunction, and excessive daytime sleepiness)
or delineate (for RBD) the magnitude of risk each of these
conveys and to establish a comparable method of measure-
ment for each. The association of a preceding tremor,
imbalance, and stiffness with later PD (all reported in single
studies) may point to early motor manifestations of the dis-
ease before a diagnosis can be made.47,48
Comorbidities and Medications
Hypertension was associated with reduced risk of PD, but
the role of selective mortality in these individuals has not
been studied. The combined analysis of studies of calcium
channel blockers suggests a mild but significant overall
reduction of PD risk. Beta blockers, on the other hand,
were associated with increased PD risk. This could, how-
ever, potentially be explained by trials of beta blockers in
those with seemingly isolated tremor. A history of diabetes
mellitus did not significantly alter risk; however, further
studies may be necessary, given that the case–control stud-
ies showed a statistically significant decrease in risk,
whereas the cohort studies, showed a statistically signifi-
cant increase in risk. Statins showed a trend of reduction
in risk of subsequent PD in this meta-analysis, which may
be due to a protective role through reduction of oxidative
stress.49 Hypercholesterolemia, obesity, and physical activ-
ity could not be included in the meta-analysis due to dif-
ferences in assessment, and the systematic review found
conflicting results.
NSAIDs are associated with risk reduction by
approximately 17%. A similar finding has recently been
published in a Cochrane review of NSAIDs preceding
PD diagnosis.50 There is increasing evidence that inflam-
mation may play a role in the pathogenesis of PD, which
may underlie this finding.31,51,52 Aspirin and acetamino-
phen/paracetamol did not modify risk significantly. The
suggestion that raised plasma urate might protect against
PD may also be related to inflammatory mechanisms,
because serum urate is a free radical scavenger and there-
fore protects against oxidative stress, which may contrib-
ute to dopaminergic neuronal loss.53
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We did not find any association of subsequent PD
with the oral contraceptive pill, surgical menopause, or
hormone replacement therapy, although further studies on
the latter are needed, given that case–control studies
showed a statistically significant decrease in risk, whereas
cohort studies showed a statistically significant increase in
risk. There was no significant association of PD and pre-
ceding cancer. Although we did not include melanoma as
a specific search term, a recent meta-analysis suggests a
positive association of established PD with melanoma, but
no association if melanoma precedes a diagnosis of PD.54
Helicobacter pylori infection has been suggested as a
risk factor for PD in recent years, but there are no stud-
ies that specifically look at H. pylori and subsequent risk
of PD. A surrogate marker for this could be gastric ulcer-
ation, but in our meta-analysis there was no association
with prior gastric ulcer and subsequent PD diagnosis.
Factors Not Included in Analysis
Age and gender were not included in this review, as they
are mainly reported in uncontrolled prevalence studies.
Thus, although some of the studies included in the anal-
ysis reported risk associated with these variables, a com-
bined risk estimate is unlikely to be representative of the
full published literature on these factors. Nevertheless,
the increased prevalence rate with increasing age and the
higher prevalence in men are well recognized, and report-
ing is therefore usually stratified by age and gender.2,55
Limitations of the Analysis
We restricted our search to articles written in English,
and therefore reports written in other languages are not
included in the analysis. Due to the large number of
studies used and the heterogeneity of methods and
reported findings, we selected variables according to the
main criterion that they can be screened for on a popula-
tion basis. Therefore, risk factors and early symptoms
not easily screened for would not have been included.
Not all studies reported estimates of risk adjusted for
confounders (eg, smoking). Where such adjustments have
been made, we have included these data in the analysis.
Risk factors were dichotomized, which ignores dose
effects. However, an essential feature of this analysis was
to define factors that could be defined in binary terms,
to allow them to be employed in combination for large-
scale screening.
Statistically significant heterogeneity was found in
the majority (24 of 30) of meta-analyses performed, sim-
ilar to what has previously been reported.56 In 16 of
these there was moderate heterogeneity (I2 ¼ 50–75%),
and in 4 there was high heterogeneity (I2 > 75%). This
is expected, because of the differences between individual
studies in, for example, case ascertainment, study popula-
tion characteristics, exposure measurement, and whether
crude or adjusted risk estimates were reported. For this
reason, the pooled estimates should be interpreted cau-
tiously, in particular for those instances of high heteroge-
neity (hypertension, statin use, previous gastric ulcera-
tion, and rural living).
Conclusions
This is the first comprehensive systematic review and
meta-analysis taking into account all risk factors for PD
suitable for screening in primary care. This report allows
comparative assessment of the evidence for, and magni-
tude of association for, the numerous proposed risk and
early disease factors of PD, and helps to understand bet-
ter their contribution to the risk of PD.
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